Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study

NCT03184597 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT03184597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03184597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
August 1, 2017
Completion date
June 30, 2021
Enrollment
4,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blepharospasm, epilepsy, neuropathy, psychiatric illness